A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Inclusion Criteria: * Meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. * Is in the non-acute phase of their illness. * Has a history of receiving and tolerating antipsychotics medication within the usual dose range employed for schizophrenia. * Participants with hypothyroidism, diabetes, high blood pressure, chronic respiratory conditions or other medical conditions could be considered if their condition is stable. Exclusion Criteria: * History of a primary DSM-5 axis I psychiatric diagnosis other than schizophrenia or schizoaffective disorder per the allowed DSM-5 criteria. * History of intellectual disability, borderline personality disorder, anxiety disorder, or organic brain syndrome. * History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia (TD). * History of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures. * History of cancer. * History or presence of sick sinus syndrome, atrioventricular (AV) block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QTc interval, or conduction abnormalities. * History of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome). * History of frequent syncope, vasovagal episodes, or epileptic seizures. * Family history of sudden cardiac death. * Has a positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV). * Had major surgery, donated, or lost 1 unit of blood within 4 weeks prior to the pre-study visit.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.